相关实验视频
Updated: Jun 15, 2025

10:37
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
9.5K
在停止Trk抑制剂治疗的患者中出现戒断疼痛
Alan Chin1, Sheila Lindsay2, Emily K Bergsland2,3
1Department of Pharmacy, University of California San Francisco Medical Center, San Francisco, CA, USA.
概括
戒断疼痛综合征可以发生在停止使用Trk抑制剂时. 管理这种疼痛的策略包括剂量调整和止痛药,强调需要明确的止痛指南.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 疼痛医学 医学 疼痛医学
背景情况:
- Trk 抑制剂是新的癌症治疗方法.
- 停止使用Trk抑制剂可能会导致戒断症状.
- 有限的文献存在于Trk抑制剂戒断疼痛.
研究的目的:
- 为了调查Trk抑制剂中止后戒断疼痛的发生率.
- 探索缓解Trk抑制剂戒断疼痛的策略.
主要方法:
- 在UCSF进行了回顾性观察研究 (2018年11月 - 2022年11月).
- 包括18岁以上的患者,他们开始使用larotrectinib或entrectinib.
- 从电子记录和药房数据库收集的数据 (n=21).
主要成果:
- 五名患者 (24%) 在停止Trk抑制剂后经历了戒断疼痛.
- 疼痛发作在停药后的几个小时到三天之间.
- 管理策略包括重新启动Trk抑制剂,逐渐减少,尽量减少剂量中断和止痛药.
结论:
- 在停止服用Trk抑制剂的患者中存在戒断疼痛综合征.
- 强调需要对患者进行坚持的教育.
- 建议制定关于停止使用Trk抑制剂的指南.
相关概念视频
Analgesia and Pain Management
553
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
553
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Desensitization and Tachyphylaxis
1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120

